Anti-Prominin-1 antibody having ADCC activity or CDC activity
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
May 13, 2014
Issued Date -
N/A
app pub date -
Jun 25, 2008
filing date -
Jun 25, 2007
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Disclosed are antibodies that bind to Prominin-1 and have ADCC activity and/or CDC activity, and pharmaceutical compositions containing those antibodies. Recombinant antibodies were produced by cloning a nucleotide sequence of the AC133 antibody variable region and it was discovered that the ADCC/CDC-inducing effect which does not exist in the original AC133 antibody is imparted to the recombinant antibodies. In the human chimeric antibody/human effector cell combination, the chimeric antibody whose constant region sequence had been converted to human IgG1/κ was found to induce strong ADCC. Humanized antibodies were prepared by grafting the AC133 antibody CDRs to a human antibody sequence, producing humanized antibodies having binding activities equivalent to the activity of the chimeric antibody. Also disclosed are unlabeled AC133 human chimeric antibodies and humanized antibodies having antitumor effects.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully